Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sharper CT scans may solve a lung disease diagnostic puzzle

NCT ID NCT07790614

Diagnosis Sponsor: Istituto Clinico Humanitas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether a newer type of CT scan, called photon-counting CT, can help doctors identify idiopathic pulmonary fibrosis (IPF) more accurately than the standard high-resolution CT scan. The study will enroll 156 adults with interstitial lung disease who need a multidisciplinary discussion to confirm their diagnosis. Researchers will compare the two scan types to see if the photon-counting version reduces the number of unclassifiable cases and increases confidence in IPF diagnoses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Photon-counting CT scan
What this could lead to
If it works, this could lead to more accurate and confident diagnoses of IPF, reducing the number of cases that remain unclassified and helping patients get the right treatment sooner.
What could go wrong
This is a diagnostic study, not a treatment trial, so it won't directly change outcomes. The new scan may not prove clearly better than the standard one, and results depend on how radiologists interpret the images.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 156 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults patients with a new diagnosis of ILD referred to the outpatient clinic of ILD of Humanitas Research Hospital, Rozzano - Milano) and with the need of a MDD discussion to reach a diagnosis will be enrolled. MDD will be leaded by two pulmonologists with 5 years of experience in ILDs. Each MDD session will include at least one additional pulmonologist, two thoracic radiologists, one thoracic surgeon, one thoracic pathologist, one rheumatologist, and at least two fellows in respiratory medicine. MDD meetings will be held every week and lasted approximately 60 minutes. Patients will be discussed using a standard case report form. Two diagnosis will be collected: the first diagnosis will be collected using the HRCT scan imaging. The second diagnosis will be collected using the PCDCT scan imaging.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 18 years of age * Any gender * Any race * Signed informed consent * ILD diagnosis with the need for a multidisciplinary discussion Exclusion Criteria: * Patients with acute exacerbation of ILD * Interstitial abnormalities that could be explained by causes different than ILD (e.g.: heart failure; viral)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CT CT photon-counting CT scan Idiopathic pulmonary fibrosis Idiopathic pulmonary fibrosis (IPF) ILD Interstitial lung disease (ILD) Interstitial lung disease due to systemic disease (telomere biology disorder) Interstitial lung diseases IPF

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Humanitas Research Hospital

    RECRUITING

    Rozzano, Italy, 20089, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.